Givaudan SMI sube a un máximo de 11 semanas después del aumento de los analistas

The share price of Givaudan, a leading Swiss company in the field of fragrance and flavouring, has seen a significant upturn over the past trading week. With a 6.8 per cent rise to CHF 3,463, it reached its highest level in eleven weeks on Friday evening, outperforming all other titles in the Swiss Market Index (SMI) by 1.6 per cent. The SMI itself recorded a modest rise of 1.6 per cent. This development follows a longer-term weakness phase in which the stock was largely ignored between July and September. Since the peak of CHF 4,670 two years ago, Givaudan has lost around 25 per cent in value, making it an undervalued title in the SMI. Analysts adjusted several price targets and valuations in the past week, which favoured the upward trend. Barclays raised its price target from CHF 3,300 to CHF 3,450, but maintained its neutral rating. JPMorgan confirmed its overweight rating and raised its price target from CHF 3,600 to CHF 3,700. The Citigroup kept its neutral rating, but adjusted its price target from CHF 3,150 to CHF 3,450. The analysts are already looking at the first quarterly report for 2026 and expect positive developments in both business areas. JPMorgan raised its forecast for organic revenue growth and estimates earnings per share (EPS) for 2026 at CHF 135.09 and for 2027 at CHF 141.81. This contrasts with the forecasts of the Zürcher Kantonalbank (ZKB), which expects an EPS of CHF 109.90 for 2026 and an EPS of CHF 133.30 for 2027. Despite these positive signals, the stock is already close to the average price target of CHF 3,458. The analyst ratings vary: nine experts recommend buying into Givaudan, eleven maintain a neutral stance, and three advise a sale. However, these recommendations are not final and could change by the next investor meeting of the week. In addition to Givaudan, other health care and financial stocks showed positive developments in the week: Galderma, Novartis, Lonza and Sandoz rose by 2.9 to 4.1 per cent, while Swiss Re gained 3.4 per cent. In turn, Zurich Insurance, UBS and the Partners Group lost between 2.2 and 2.4 per cent.